Gain Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Gain Therapeutics

08/11/2024 16:47

* Gain Therapeutics Inc  GANX.OQ   GANX.O  is expected
to show no
change in quarterly revenue when it reports  results on November
12 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Gain Therapeutics Inc is
for a
loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gain
Therapeutics
Inc is $8.00​, above​ its last closing price of $2.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.19       -0.20      -0.42     Missed  -110
 Mar. 31 0001  -0.29       -0.29      -0.22     Beat    24.8
 Dec. 31 2023  -0.30       -0.32      -0.36     Missed  -11.6​
 Sep. 30 2023  -0.45       -0.45      -0.37     Beat    17
 ​​Jun.        -0.32       -0.31      -0.62     Missed  -101.6
 30 2023                                                
 Mar. 31 2023  -0.40       -0.39      -0.43     Missed  -9.3​
 Dec. 31 2022  -0.38       -0.38      -0.39     Missed  -3.3
 Sep. 30 2022  -0.46       -0.46      -0.38     Beat    17.4
 This summary was machine generated November 8 at 16:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)